Single‐center survey of incidental imaging findings on computed tomography in patients with psoriasis on biologic therapy

Abstract

Psoriasis is one of the most common chronic inflammatory skin diseases and predominantly affects the skin and joints. 1,2 Various comorbidities and risk factors interact with each other and affect the pathogenesis of psoriasis. 3 Metabolic syndrome is strongly associated with the onset and exacerbation of psoriasis, and patients with psoriasis are at increased risk of cardiovascular disease, which is ascribed not only to metabolic syndrome but also to chronic systemic inflammation. 4 Additionally, patients with psoriasis have an increased risk of cancer. 5 Recently, the concept of psoriatic march has been widely accepted in the pathogenesis of psoriasis. 6 In patients with moderate-to-severe psoriasis, systemic therapies are required to control the disease, and biologics can provide significant

Incidental computed tomography findings in patients with psoriatic arthritis: a comparison with those in patients with psoriasis vulgaris

“…In patients with moderate-to-severe psoriasis, CT frequently reveals fatty liver disease, urolithiasis, and gallstones [2]. In this past study, multivariate logistic regression was performed to estimate the effect of psoriasis while adjusting for confounding factors such as age, body mass index, sex, type 2 diabetes mellitus, hypertension, and dyslipidemia [2]. The results showed that psoriasis was a risk factor for fatty liver disease, urolithiasis, and gallstones.…”

“…

Dear Editors, Psoriasis is one of the most common immune-mediated, chronic inflammatory diseases that predominantly affect the skin and joints [1]. Recently, we demonstrated that fatty liver disease, urolithiasis, and gallstones are frequently observed upon computed tomography (CT) of patients with psoriasis, and that psoriasis is a risk factor for the development of such comorbidities [2]. The aim of this study was to determine whether specifically the presence of psoriatic arthritis (PsA) is a risk factor for fatty liver disease, urolithiasis, and gallstones.This study was approved by the Ethical Committee of Jichi Medical University.

…”

“…The aim of this study was to determine whether specifically the presence of psoriatic arthritis (PsA) is a risk factor for fatty liver disease, urolithiasis, and gallstones.This study was approved by the Ethical Committee of Jichi Medical University. Details of the methods used in this study have already been reported [2]. Patients with psoriasis who received biologics between 1 January 2020 and 28 February 2021 at Jichi Medical University Hospital were enrolled in this study.…”

“…This study was approved by the Ethical Committee of Jichi Medical University. Details of the methods used in this study have already been reported [2]. Patients with psoriasis who received biologics between 1 January 2020 and 28 February 2021 at Jichi Medical University Hospital were enrolled in this study.…”

“…and cardiovascular events among patients with PsA is significantly higher than those in patients with psoriasis without arthritis [4]. In patients with moderate-to-severe psoriasis, CT frequently reveals fatty liver disease, urolithiasis, and gallstones [2]. In this past study, multivariate logistic regression was performed to estimate the effect of psoriasis while adjusting for confounding factors such as age, body mass index, sex, type 2 diabetes mellitus, hypertension, and dyslipidemia [2].…”